Mexican President Andrés Manuel López Obrador is concerned Latin America won’t be the first in line for a coronavirus vaccine. So he has teamed up with Argentina to produce one.



LEILA FADEL, HOST:

Mexico has registered the third-highest number of COVID deaths in the world, more than 56,000. Its president, though, is reassuring his people that they will have access to a coronavirus vaccine once approved. Mexico and Argentina have teamed up with a major drug company to begin producing a vaccine for Latin America as soon as November. NPR’s Carrie Kahn reports.

CARRIE KAHN, BYLINE: That November production start date is optimistic. But eager to give Mexicans some good news on the coronavirus front, President Andres Manuel Lopez Obrador has been talking up the new agreement Mexico and Argentina have signed with the AstraZeneca pharmaceutical company.

(SOUNDBITE OF ARCHIVED RECORDING)

PRESIDENT ANDRES MANUEL LOPEZ OBRADOR: (Speaking Spanish).

KAHN: “This gives us certainty, the confidence that we will come out of this nightmare,” said Lopez Obrador in a video posted on social media. Mexico’s richest man, Carlos Slim, says he’ll chip in to help with startup costs. Mexico has long been concerned about richer nations snatching up anti-COVID resources before poor countries. Lopez Obrador says the new vaccine agreement ensures Mexico’s place in the vaccine pipeline. Producing it in Latin America will also lower costs, estimated to be about $4 a dose.

Today, Lopez Obrador said what’s important is to get an effective vaccine, even if it’s the one Russia announced last week that’s yet to go through extensive trials.

(SOUNDBITE OF ARCHIVED RECORDING)

LOPEZ OBRADOR: (Speaking Spanish).

KAHN: “And I’ll be the first to be vaccinated,” he said.

Carrie Kahn, NPR News, Mexico City.

(SOUNDBITE OF MUSIC)

Copyright © 2020 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.